Berna Beverloo

995 total citations
18 papers, 260 citations indexed

About

Berna Beverloo is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Berna Beverloo has authored 18 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 8 papers in Molecular Biology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Berna Beverloo's work include Acute Lymphoblastic Leukemia research (6 papers), Multiple Myeloma Research and Treatments (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Berna Beverloo is often cited by papers focused on Acute Lymphoblastic Leukemia research (6 papers), Multiple Myeloma Research and Treatments (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Berna Beverloo collaborates with scholars based in Netherlands, France and United States. Berna Beverloo's co-authors include Gregor Verhoef, Pieter Sonneveld, Bronno van der Holt, Rudi W. Hendriks, Roland Kanaar, Katsuhiro Hanada, Alex Maas, Pamela Kearns, Jan H.J. Hoeijmakers and Monique L. den Boer and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Blood.

In The Last Decade

Berna Beverloo

16 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Berna Beverloo Netherlands 6 159 143 68 60 50 18 260
Ya‐Zhen Qin China 11 187 1.2× 171 1.2× 70 1.0× 53 0.9× 63 1.3× 51 340
Teresa Sadras Australia 10 107 0.7× 150 1.0× 37 0.5× 39 0.7× 66 1.3× 22 301
Francesca Messa Italy 7 166 1.0× 152 1.1× 28 0.4× 67 1.1× 63 1.3× 28 255
Darin P. O’Brien United States 7 299 1.9× 331 2.3× 40 0.6× 70 1.2× 49 1.0× 14 503
W.-K. Hofmann Germany 7 120 0.8× 159 1.1× 61 0.9× 36 0.6× 51 1.0× 9 268
Kathleen C. Rayeroux Australia 6 109 0.7× 109 0.8× 50 0.7× 91 1.5× 29 0.6× 10 224
Jean‐Valère Malfuson France 8 143 0.9× 142 1.0× 50 0.7× 42 0.7× 29 0.6× 15 250
L C Chan Hong Kong 7 194 1.2× 221 1.5× 32 0.5× 101 1.7× 74 1.5× 10 399
Matthew Smith United Kingdom 4 222 1.4× 162 1.1× 21 0.3× 90 1.5× 52 1.0× 8 306
Antonio Spadano Italy 11 281 1.8× 184 1.3× 93 1.4× 153 2.5× 59 1.2× 32 404

Countries citing papers authored by Berna Beverloo

Since Specialization
Citations

This map shows the geographic impact of Berna Beverloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berna Beverloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berna Beverloo more than expected).

Fields of papers citing papers by Berna Beverloo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berna Beverloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berna Beverloo. The network helps show where Berna Beverloo may publish in the future.

Co-authorship network of co-authors of Berna Beverloo

This figure shows the co-authorship network connecting the top 25 collaborators of Berna Beverloo. A scholar is included among the top collaborators of Berna Beverloo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berna Beverloo. Berna Beverloo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Abrahamsson, Jonas, Berna Beverloo, Eveline S.J.M. de Bont, et al.. (2018). Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO‐DBH‐AML study. British Journal of Haematology. 183(4). 618–628. 4 indexed citations
2.
Mulet‐Lazaro, Roger, Berna Beverloo, Marije Havermans, et al.. (2018). Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression. Blood. 132(Supplement 1). 2766–2766. 1 indexed citations
3.
Bruinink, Davine Hofste op, Vincent van der Velden, Mark van Duin, et al.. (2017). The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow. Blood. 130. 4368–4368.
4.
5.
Bruinink, Davine Hofste op, Eric M. Bindels, Mathijs A. Sanders, et al.. (2016). Abstract 5023: Multiple myeloma with a clonal del17p aberration is characterized by somatic TP53 mutations, which negatively affect prognosis in this cytogenetic subgroup. Cancer Research. 76(14_Supplement). 5023–5023.
6.
Boer, Judith M., Aurélie Boeree, Berna Beverloo, et al.. (2015). Clinical Relevance of Tyrosine Kinase Fusion Genes in Pediatric BCR-ABL1-like Acute Lymphoblastic Leukemia. Blood. 126(23). 3735–3735. 3 indexed citations
7.
8.
Zwaan, C. Michel, Carmelo Rizzari, Françoise Méchinaud, et al.. (2013). Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium. Journal of Clinical Oncology. 31(19). 2460–2468. 66 indexed citations
9.
Zwaan, C. Michel, Carmelo Rizzari, Vincent H. J. van der Velden, et al.. (2008). Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.. Blood. 112(11). 3241–3241. 6 indexed citations
10.
Wu, Ka Lung, Berna Beverloo, Henk M. Lokhorst, et al.. (2007). Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma. British Journal of Haematology. 136(4). 615–623. 48 indexed citations
11.
Wu, Ka Lung, et al.. (2007). Sequential Analysis of Chromosome Aberrations in Multiple Myeloma During Disease Progression. Clinical Lymphoma & Myeloma. 7(4). 280–285. 4 indexed citations
12.
Zwaan, C. Michel, Monique L. den Boer, Berna Beverloo, et al.. (2006). Dasatinib (SPRYCEL®) in Children and Adolescents with Relapsed or Refractory Leukemia: Preliminary Results of the CA180018 Phase I/II Study.. Blood. 108(11). 2162–2162. 2 indexed citations
13.
Budzowska, Magda, Jeroen Essers, Harm de Waard, et al.. (2004). Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage‐dependent recombination. The EMBO Journal. 23(17). 3548–3558. 54 indexed citations
14.
Beverloo, Berna, et al.. (2004). Extensive Chromosome Instability in Acute Myeloid Leukemia Is Associated with Critical Telomere Shortening.. Blood. 104(11). 3376–3376. 1 indexed citations
15.
Holt, Bronno van der, Pieter Sonneveld, Alan K. Burnett, et al.. (2004). Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia.. Blood. 104(11). 863–863. 2 indexed citations
16.
Wouters, Carine, et al.. (2001). Deletions at chromosome regions 7q11.23 and 7q36 in a patient with Williams syndrome. American Journal of Medical Genetics. 102(3). 261–265. 6 indexed citations
17.
Michaux, Lucienne, Iwona Włodarska, Michel Stul, et al.. (2000). MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23. Genes Chromosomes and Cancer. 29(1). 40–47. 59 indexed citations
18.
Michaux, Lucienne, Judith Dierlamm, Michel Stul, et al.. (1998). Amplification of chromosome 11q23 involving the MLL gene is recurrently observed in myeloid leukemias.. Blood. 92(10). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ya‐Zhen Qin Breakdown of academic impact, for papers by Teresa Sadras Breakdown of academic impact, for papers by Francesca Messa Breakdown of academic impact, for papers by Darin P. O’Brien Breakdown of academic impact, for papers by W.-K. Hofmann Breakdown of academic impact, for papers by Kathleen C. Rayeroux Breakdown of academic impact, for papers by Jean‐Valère Malfuson Breakdown of academic impact, for papers by L C Chan Breakdown of academic impact, for papers by Matthew Smith Breakdown of academic impact, for papers by Antonio Spadano
Rankless by CCL
2026